Hypometabolism, Alzheimer’s Disease, and Possible Therapeutic Targets: An Overview
Cells · 08.08.2023 · 12 (16) · 2019
DOI: 10.3390/cells12162019 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 08.08.2023. Verfasst von Snehal Raut und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Foundational Medical Studies, Oakland University William Beaumont School of Medicine, Rochester, MI 48309, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 214 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIDA NIH HHS, National Institutes of Health/National Institute.
Themen: Demenz
Abstract (Originalsprache)
The brain is a highly dynamic organ that requires a constant energy source to function normally. This energy is mostly supplied by glucose, a simple sugar that serves as the brain’s principal fuel source. Glucose transport across the blood–brain barrier (BBB) is primarily controlled via sodium-independent facilitated glucose transport, such as by glucose transporter 1 (GLUT1) and 3 (GLUT3). However, other glucose transporters, including GLUT4 and the sodium-dependent transporters SGLT1 and SGLT6, have been reported in vitro and in vivo. When the BBB endothelial layer is crossed, neurons and astrocytes can absorb the glucose using their GLUT1 and GLUT3 transporters. Glucose then enters the glycolytic pathway and is metabolized into adenosine triphosphate (ATP), which supplies the energy to support cellular functions. The transport and metabolism of glucose in the brain are impacted by several medical conditions, which can cause neurological and neuropsychiatric symptoms. Alzheimer’s disease (AD), Parkinson’s disease (PD), epilepsy, traumatic brain injury (TBI), schizophrenia, etc., are a few of the most prevalent disorders, characterized by a decline in brain metabolism or hypometabolism early in the course of the disease. Indeed, AD is considered a metabolic disorder related to decreased brain glucose metabolism, involving brain insulin resistance and age-dependent mitochondrial dysfunction. Although the conventional view is that reduced cerebral metabolism is an effect of neuronal loss and consequent brain atrophy, a growing body of evidence points to the opposite, where hypometabolism is prodromal or at least precedes the onset of brain atrophy and the manifestation of clinical symptoms. The underlying processes responsible for these glucose transport and metabolic abnormalities are complicated and remain poorly understood. This review article provides a comprehensive overview of the current understanding of hypometabolism in AD and potential therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Foundational Medical Studies, Oakland University William Beaumont School of Medicine, Rochester, MI 48309, USA.
- Department of Biological and Biomedical Sciences, Oakland University, Rochester, MI 48309, USA.
ORCID-Profile: Snehal Raut, Michael Powers, Luca Cucullo
Förderung
- NINDS NIH HHS
- NIDA NIH HHS
- National Institutes of Health/National Institute
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Raut, S., Bhalerao, A., Powers, M., Gonzalez, M., Mancuso, S., & Cucullo, L. (2023). Hypometabolism, Alzheimer’s Disease, and Possible Therapeutic Targets: An Overview. Cells, 12(16), 2019. https://doi.org/10.3390/cells12162019
Vancouver
Raut S, Bhalerao A, Powers M, Gonzalez M, Mancuso S, Cucullo L. Hypometabolism, Alzheimer’s Disease, and Possible Therapeutic Targets: An Overview. Cells. 2023;12(16):2019. doi:10.3390/cells12162019
BibTeX
@article{Raut2023,
author = {Raut, Snehal and Bhalerao, Aditya and Powers, Michael and Gonzalez, Minelly and Mancuso, Salvatore and Cucullo, Luca},
title = {Hypometabolism, Alzheimer’s Disease, and Possible Therapeutic Targets: An Overview},
journal = {Cells},
year = {2023},
volume = {12},
number = {16},
pages = {2019},
doi = {10.3390/cells12162019}
}
EUVIMED